A Long-Term Follow-up Study of Subjects Who Participated in a Clinical Trial in Which Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) Was Administered for the Treatment of Chronic Hepatitis C
A Long-Term Follow-up Study of Subjects Who Participated in a Clinical Trial in Which Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) Was Administered for the Treatment of Chronic Hepatitis C
The primary purpose of this study is to determine whether the hepatitis C virus continues to remain unable to be detected in subjects who were previously treated with Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) and achieved sustained virologic response.
Inclusion Criteria
Exclusion Criteria:
Chapel Hill, North Carolina 27599-7584, United States
Ciudad de Buenos Aires, Buenos Aires C1121ABE, Argentina
Prov. Buenos Aires, Buenos Aires 1629, Argentina
Prov de Santa Fe, Santa Fe Province 2000, Argentina
Darlinghurst Nsw, New South Wales 2010, Australia
Woollongabba, Queensland 4102, Australia
Clayton Vic, Victoria 3168, Australia
Cisanello (pisa), 56124, Italy
Viale Del Policlinico, 155, 00161, Italy
Ogaki-shi, Gifu 5038502, Japan
Amagasaki-shi, Hyōgo 6608511, Japan
Kawasaki-shi, Kanagawa 2138587, Japan
Osaka-sayama-shi, Osaka 5898511, Japan
Suita-shi, Osaka 5650871, Japan
Iruma-gun, Saitama 3500495, Japan
Bunkyo-ku, Tokyo 1138655, Japan
Minato-ku, Tokyo 1058470, Japan
Musashino-shi, Tokyo 1808610, Japan
Shinagawa-ku, Tokyo 1428666, Japan
Chuo-shi, Yamanashi 4093898, Japan